Ocugen

Ocugen CEO Offloads 525,991 Shares Under Pre-Set Plan as Stock Hovers Near 52-Week Low

Brett Shapiro -

Ocugen’s 2027 Data Crossroads: New Leadership, Fresh Capital, and a Binary Bet on Two Trials

Ocugen’s Insider Buy Sends a Quiet Signal as Clinical Catalysts Loom

kashif hafeez -

Ocugen’s Countdown to 2027: Regulatory Path Clears as Cash Runway Extends, but Stock Remains Stuck in Neutral

Brett Shapiro -

Ocugen’s Gene-Therapy Pipeline: Three BLAs, One Platform, and a 670% Analyst Gap

Brett Shapiro -

Ocugen: Insider Buying Signals Confidence as Short Sellers Circle and Pipeline Nears Critical Data

Ocugen’s Summer of Data: Short Sellers Stand at 26% as Gene Therapy Milestones Converge

angelina -

Ocugen Faces a Pivotal 90 Days as Retinitis Pigmentosa and Stargardt Data Converge

angelina -

Ocugen’s CFO Buys In as the Pipeline Enters a Defining Stretch

Brett Shapiro -

Ocugen Charts a Three-Year Path to FDA Filings With $112M War Chest and a Novel Gene Therapy Platform

kashif hafeez -

Ocugen’s Refinancing Cuts Debt Burden as Gene Therapy Data Buoy Outlook — But Stock Slips on Dilution Worries

kashif hafeez -

Ocugen’s Pipeline Accelerates into a Pivotal Summer as Convertible Debt Fuels and Frays Investor Sentiment

angelina -

Ocugen’s Third Quarter: A Crucible of Clinical Data and Capital Concerns

Ocugen Navigates a Critical Juncture with Cash and Clinical Catalysts

angelina -

Analyst Confidence Rises for Ocugen’s Gene Therapy Pipeline

angelina -
123Page 1 of 3